3722 related articles for article (PubMed ID: 7081141)
21. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
22. Enhancement by hyperthermia of the effect of BCNU against the EMT6 mouse tumor.
Twentyman PR; Morgan JE; Donaldson J
Cancer Treat Rep; 1978 Mar; 62(3):439-43. PubMed ID: 647699
[TBL] [Abstract][Full Text] [Related]
23. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.
Hill GJ; Metter GE; Krementz ET; Fletcher WS; Golomb FM; Ramirez G; Grage TB; Moss SE
Cancer Treat Rep; 1979; 63(11-12):1989-92. PubMed ID: 393384
[No Abstract] [Full Text] [Related]
24. Effect of administration schedules on the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by misonidazole in subcutaneous 9L tumors.
Wong KH; Zhang H; Wallen CA; Wheeler KT
Int J Radiat Oncol Biol Phys; 1992; 23(4):831-9. PubMed ID: 1618675
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
26. Human malignant melanoma: preclinical and clinical drug evaluation.
Osieka R
Behring Inst Mitt; 1984 May; (74):353-67. PubMed ID: 6383327
[TBL] [Abstract][Full Text] [Related]
27. Chemosensitivity spectrum of a human pleural mesothelioma xenograft grown in athymic rats.
Lindén CJ
In Vivo; 1991; 5(4):375-80. PubMed ID: 1810423
[TBL] [Abstract][Full Text] [Related]
28. The radiosensitizing effect of metronidazole and misonidazole (Ro-07-0582) on a human malignant melanoma grown in the athymic mutant nude mouse.
Rofstad EK; Brustad T
Br J Radiol; 1978 May; 51(605):381-6. PubMed ID: 638410
[TBL] [Abstract][Full Text] [Related]
29. Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies.
Smyth MJ; Pietersz GA; McKenzie IF
Cancer Res; 1987 Jan; 47(1):62-9. PubMed ID: 3791221
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
[TBL] [Abstract][Full Text] [Related]
31. Glucocorticoid effect on melphalan cytotoxicity, cell-cycle position, cell size, and [3H]uridine incorporation in one of three human melanoma cell lines.
Benckhuijsen C; Osman AM; Hillebrand MJ; Smets LA
Cancer Res; 1987 Sep; 47(18):4814-20. PubMed ID: 3621177
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Nelson DF; Schoenfeld D; Weinstein AS; Nelson JS; Wasserman T; Goodman RL; Carabell S
Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1143-51. PubMed ID: 6347995
[TBL] [Abstract][Full Text] [Related]
33. Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
Gola A; Kuliczkowski K; Sedek K
Neoplasma; 1992; 39(1):35-8. PubMed ID: 1528303
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
Hinchliffe M; McNally NJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of melphalan crosslink enhancement by misonidazole pretreatment.
Taylor YC; Sawyer JM; Hsu B; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1603-7. PubMed ID: 6480448
[TBL] [Abstract][Full Text] [Related]
36. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Hirst DG; Brown JM; Hazlehurst JL
Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Siemann DW
Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
Mabel JA; Merker PC; Sturgeon ML; Wodinsky I; Geran RI
Cancer; 1978 Oct; 42(4):1711-9. PubMed ID: 81716
[TBL] [Abstract][Full Text] [Related]
39. Effect of combined misonidazole and accelerated neon ions on a human melanoma transplanted into nude mice.
Guichard M; Tenforde T; Curtis S; Malaise EP
Radiology; 1982 Jan; 142(1):219-23. PubMed ID: 6796997
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
Cancer Treat Rep; 1986 Oct; 70(10):1167-71. PubMed ID: 3756939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
